Addex Therapeutics' Advancements in Allosteric Modulation and Collaborative Ventures in CNS Pharmaceuticals |Tim DyerCo , CEO, Addex Therapeutics Ltd. 00:10:00
Tim Dyer, CEO of Addex Therapeutics, discusses the company's progress in allosteric modulation, particularly in CNS-focused pharmaceuticals. Their collaboration with Johnson & Johnson on a phase two study for epilepsy, alongside developments in chronic cough, schizophrenia, and cognition treatments, showcases their innovative approach. With a strategic focus on advancing programs and securing partnerships amid challenging capital markets, Addex aims for substantial growth with seven programs in the pipeline.
